Last reviewed · How we verify
HS-10374 tablets
At a glance
| Generic name | HS-10374 tablets |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (PHASE1)
- A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis (PHASE2)
- A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (PHASE3)
- Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (PHASE2)
- A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (PHASE2)
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HS-10374 tablets CI brief — competitive landscape report
- HS-10374 tablets updates RSS · CI watch RSS
- Hansoh BioMedical R&D Company portfolio CI